Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2020 Oct 1;126(19):4423-4431.
doi: 10.1002/cncr.33100. Epub 2020 Jul 28.

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Sharon Elad  1 , Karis Kin Fong Cheng  2 , Rajesh V Lalla  3 , Noam Yarom  4 , Catherine Hong  5 , Richard M Logan  6 , Joanne Bowen  7 , Rachel Gibson  8 , Deborah P Saunders  9 , Yehuda Zadik  10 , Anura Ariyawardana  11 , Maria Elvira Correa  12 , Vinisha Ranna  13 , Paolo Bossi  14 ; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO)
Collaborators, Affiliations
Practice Guideline

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Sharon Elad et al. Cancer. .

Erratum in

Abstract

Background: Mucositis is a significant toxicity of cancer therapy with numerous systemic sequelae. The goal of this systematic review was to update the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for the management of mucositis.

Methods: The literature was reviewed systematically to identify interventions for mucositis. Studies were rated according to the presence of major and minor flaws according to previously published criteria. The body of evidence for each intervention and in each treatment setting was assigned a level of evidence based on previously published criteria. Guidelines were developed based on the level of evidence, with 3 possible guideline determinations: recommendation, suggestion, or no guideline possible.

Results: The guideline covers evidence from 1197 publications related to oral or gastrointestinal mucositis. Thirteen new guidelines were developed for or against the use of various interventions in specific treatment settings, and 11 previous guidelines were confirmed after aa review of new evidence. Thirteen previously established guidelines were carried over because there was no new evidence for these interventions.

Conclusions: The updated MASCC/ISOO Clinical Practice Guidelines for mucositis provide professional health caregivers with a clinical setting-specific, evidence-based tool to help with the management of mucositis in patients who have cancer.

Keywords: Multinational Association of Supportive Care in Cancer and International Society for Oral Oncology (MASCC/ISOO); cancer; gastrointestinal; guidelines; mucositis; oral.

PubMed Disclaimer

Conflict of interest statement

According to Multinational Association of Supportive Care in Cancer (MASCC) guidelines policy, employees of commercial entities were not eligible to serve on this MASCC Guidelines Panel. Sharon Elad reports consultation fees from Falk Pharma, outside the submitted work. Rajesh V. Lalla reports institutional research support from Novartis, Oragenics, and Sucampo Pharma, outside the submitted work; grants and personal fees from Galera Therapeutics, outside the submitted work; personal fees from Alira Health, Colgate Oral Pharmaceuticals, Eagle Pharma, Enlivity, Ingalfarma SA, Meiji Seika Pharma, Monopar Therapeutics, Mundipharma, and Sucampo Pharma, outside the submitted work; stock ownership in Logic Biosciences; and has a patent pending (WO 2019/217536 A2; University of Connecticut, applicant). Deborah P. Saunders reports institutional research support from Galera Therapeutics. Paolo Bossi reports personal fees from Merck Serono, Roche, Sanofi, Merck Sharp & Dohme, Sun Pharma, AstraZeneca, Kyowa Hakko Kyrin, AstraZeneca, Bristol‐Myers Squibb, Helsinn, and Glaxo‐Smith‐Kline, outside the submitted work. The remaining authors made no disclosures.

References

    1. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem‐cell transplantation. J Clin Oncol. 2001;19:2201‐2205. - PubMed
    1. Vera‐Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem‐cell transplantation in patients with hematologic malignancies. Support Care Cancer. 2007;15:491‐496. - PubMed
    1. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy‐induced mucositis. Cancer. 2003;98:1531‐1539. - PubMed
    1. Keefe DM, Gibson RJ, Hauer‐Jensen M. Gastrointestinal mucositis. Semin Oncol Nurs. 2004;20:38‐47. - PubMed
    1. Rubenstein EB, Peterson DE, Schubert M, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy‐induced oral and gastrointestinal mucositis. Cancer. 2004;100:2026‐2046. - PubMed

Publication types